Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
Authors:
- Claus KambyCKClaus Kamby
- Bent EjlertsenBEBent Ejlertsen
- Søren ColdSCSøren Cold
- Marianne EwertzMEMarianne Ewertz
- Erik H. JacobsenEJErik H. Jacobsen
- Preben PhilipPPPreben Philip
- Knud A. MøllerKMKnud A. Møller
- Disa JensenDJDisa Jensen
- Susanne MøllerSMSusanne Møller
- 1 January 2008
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (4) , 718-724
Abstract
From January 1, 1990 to December 31, 1994, DBCG conducted a randomised trial in 1 615 postmenopausal women with operable, high-risk, receptor-positive or -unknown breast cancer. The patients were after surgery randomised to Tamoxifen for 1 year (TAM1), Tamoxifen for 2 years (TAM 2) or Tamoxifen for 6 months followed by megestrol acetate for 6 months (TAM/MA). When the preplanned sample size of 1 500 patients was reached it was decided to continue randomisation to TAM1 or TAM2 and the study was finally closed December 31, 1996. With a median follow-up of more than 10 years, there was no difference in disease-free survival (DFS) or overall survival (OS) among the three treatment arms. Similar results were obtained in the original and extended comparisons of Tamoxifen for 1 versus 2 years. A multivariate analysis in the per-protocol treated patients did not show significant differences in hazard ratios for DFS or OS among the three arms. Side-effects were rare but more common in the TAM2 and TAM/MA arms.Keywords
This publication has 10 references indexed in Scilit:
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialThe Lancet, 2005
- High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year UpdateClinical Breast Cancer, 2004
- Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind TrialJournal of Clinical Oncology, 2000
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI: Journal of the National Cancer Institute, 1996
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI: Journal of the National Cancer Institute, 1996
- Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancerBreast Cancer Research and Treatment, 1990
- Adjuvant Treatment of Postmenopausal Patients with High Risk Primary Breast Cancer: Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 CActa Oncologica, 1988
- Endocrine Therapy of Advanced Breast CancerActa Oncologica, 1988